Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.

about

Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.

Item

http://www.wikidata.org/entity/Q47779251

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.

@en

Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.

@nl

type

Item

label

Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.

@en

Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.

@nl

prefLabel

Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.

@en

Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.

@nl

P1476

Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.

@en

P2093

Isao Kamae

http://www.w3.org/2001/XMLSchema#string

Rosarin Sruamsiri

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis

Pharmaceutical regulation in Europe and its impact on corporate R&D.

Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment.

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

In Japan, all-payer rate setting under tight government control has proved to be an effective approach to containing costs.

Multiple criteria decision analysis for health technology assessment.

Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade.

Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents.

The generic drug market in Japan: will it finally take off?

Determinants of branded prescription medicine prices in OECD countries.

P304

1-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737167.2018.1394187

http://www.w3.org/2001/XMLSchema#string

P50

Jörg Mahlich

P577

2017-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29039214

http://www.w3.org/2001/XMLSchema#string